Navigation Links
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Date:10/8/2008

fluenza vaccine generated broader, more balanced antibody responses than unformulated vaccine, and also generated influenza-specific T-cell responses. Adjusting the ratio of Vaxfectin(R) to vaccine drove substantial increases in either antibody or T-cell responses, without reducing the other type of response, compared with unformulated vaccine. The ability to favor primarily antibody or T-cell responses could provide important advantages in developing vaccines for specific applications.

H5N1 Pandemic Influenza Vaccine Phase 1 Trial Update

Vical reported in July that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines achieved potentially protective levels of antibody responses (H5 hemagglutination inhibition, or HI, titers of at least 40 and at least a four-fold increase from baseline) in at least 50% and up to 67% of evaluable subjects in the higher dose cohorts in a 100-subject Phase 1 trial.

Following injections at Days 0 and 21, responses peaked by Day 56, and more than 90% of the responders had sustained responses through the last measurement (Day 84) at the time of the preliminary analysis. Expanded data presented today shows that in the two cohorts receiving the highest H5 DNA dose (1 mg), 80% to 100% of the responders had sustained responses through Day 182. Similar results for a vaccine deployed during the early stages of a pandemic outbreak could provide substantial protection to the at-risk population and potentially alter the course of the pandemic.

These results support further development of Vaxfectin(R)-formulated DNA vaccines, and could position them as potential alternatives to conventional vaccines. DNA vaccines are fundamentally different from conventional vaccines because they do not contain any part of the virus itself, and may offer compelling advantages in response to a pandemic outbreak because of significantly reduced development and manufacturing times. Vical is currently seeking funding to
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Indien, August 1, 2014 ... Inc. gaben heute bekannt, vor kurzem für ... zur Schmerzbehandlung nach chirurgischen Eingriffen eine kommerzielle ... der Europäischen Union und weiterer europäischer Länder ... und mit Ropivacain gefüllte OneDose ReadyfusOR später ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
(Date:7/31/2014)... Care®, Inc. (NASDAQ: TNDM ), a medical device ... its financial results for the quarter ended June 30, 2014. ... to the same period of 2013: , Sales grew ... t:slim Pump shipments grew 64 percent to 2,235 pumps from ... 30, 2014 to the same period of 2013: , ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4
... SYK ) reported operating results for the quarter ... Third Quarter Highlights Net sales increased 7.0% ... million Orthopaedic Implants sales increased 1.3% on a constant ... increased 16.3% on a constant currency basis (16.1% as reported) ...
... Initiatives, Inc. (Nasdaq: MTXX ), an over-the-counter healthcare ... second quarter and six months ended September 30, 2010, will ... 2010. An earnings conference call will be held the following ... To access the teleconference, please call (877) 718-5108 ...
Cached Medicine Technology:Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results 2
(Date:8/1/2014)... 2014 AAGL, a premiere professional ... is pleased to announce a joint venture with ... and Europe, which strongly recommends every hospital teaching ... endoscopic dry lab for training in an effort ... skills. , Endoscopy is the use of small ...
(Date:8/1/2014)... August 01, 2014 We are ... ES-AMI on AWS Marketplace. EspressReport ES-AMI delivers enterprise ... at $0.50 per hour (AWS infrastructure charges apply). ... easy-to-use enterprise BI and operational reporting system with ... and ad hoc reporting. It allows users to ...
(Date:8/1/2014)... 01, 2014 Get the report here: ... PitchBook presents the 3Q 2014 Private Equity Breakdown report ... investment, exits and fundraising activity in the second quarter ... plan for private equity endeavors for the remainder of ... download it now. , About Merrill DataSite , Merrill ...
(Date:7/31/2014)... Just in time for Washington’s unusually hot ... featuring new summertime drink specials on their famed cocktail ... throughout the season. , A longtime favorite ... Seattle’s best happy hour is well-known for its locally-sourced ... location’s 25th anniversary this summer, Duke is now debuting ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
Breaking Medicine News(10 mins):Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3
... ARBOR, Mich., Dec. 3 A majority of Americans support ... confidence that the cost, quality, value or accessibility of medical ... survey released today by Thomson Reuters. , Sixty percent of ... included in final healthcare reform legislation. Only about one in ...
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Sterilization Technologies: The ... Details the North American sales of capital equipment to ... compound annual growth rate for 2009-2014. , Explains how ...
... , WASHINGTON, Dec. 2 In response to a press ... ," an initiative from the U.S. Anti-Doping Agency (USADA) ... trade association representing the dietary supplement industry, issued the following statement: ... President and CEO: , "We share the concerns of ...
... ... Website traffic rises 8%. According to Coremetrics, a marketing optimization company, ... 2008. , Contrast those statistics to Boston,s Bella Sante Day ... Monday Internet sales rose 59%" - said Tiffany Amorosino, COO of Bella ...
... greater the sleep disturbances, study finds , WEDNESDAY, Dec. 2 ... to increase the risk of sleep apnea, say U.S. researchers. ... drug damages the brain and can cause immediate and dangerous ... of the Johns Hopkins School of Medicine in Baltimore, said ...
... 2 Huntington Memorial Hospital,s stroke program has received ... designating the hospital a primary stroke center. This ... center" hospitals throughout Los Angeles County. , ... more important, a wonderful benefit for Pasadena and its ...
Cached Medicine News:Health News:Thomson Reuters Survey: Most Americans Support Public Option in Healthcare Reform Legislation but Are Skeptical Healthcare Will Improve in 2010 2Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 2Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 3Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 5Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 6Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 7Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 8Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 9Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 10Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 11Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 12Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 13Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 2Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 3Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2
... Insulin-like growth factor binding protein-3 (IGFBP-3) is the ... postnatal serum, as a component of the ~150 ... a molecule of IGF-I or IGF-II and ALS, ... actions of the IGFs. The molar concentration of ...
... Growth hormone (GH) is a monomeric protein ... anterior pituitary gland. GH is released from ... pulsatile manner under the regulatory control of ... [1]. The timing and frequency of GH ...
... hormone (GH) is a monomeric protein produced ... pituitary gland. GH is released from the ... manner under the regulatory control of hypothalamic ... The timing and frequency of GH release ...
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
Medicine Products: